Harneys has enlarged its two-partner corporate team with the hiring of Alan Au for its Hong Kong office.
New partner Au – formerly an associate at Fangda Partners, Shearman & Sterling, Bird & Bird, Robertsons and Sidley Austin – specialises in the capital markets sector involving privatisations, IPOs, M&A, private and public equity and debt offerings, SPAC and de-SPAC transactions, joint ventures, and share option and award schemes.
Before qualifying as a lawyer in 2012, Au was a medical specialist at GlaxoSmithKline and Stiefel Laboratories. His strong science and pharmaceutical background facilitates his acting on biotech companies’ IPOs, such as JW Therapeutics, Hua Medicine and Frontage Holdings, in Hong Kong.
He also advised two buyer consortiums in New Frontier Health’s privatisation and the 51job privatisation from the US bourse, which were awarded as Deal of the Year in 2022 and 2021, respectively, by China Business Law Journal.